ImmunOs Therapeutics leverages an HLA-based technology platform to develop first-in-class therapeutics targeting cancer and autoimmune diseases. Its lead program, IOS-1002, is a multi-functional HLA-fusion protein that binds specific LILRB and KIR receptors to stimulate both the innate and adaptive immune systems. The company is developing IOS-1002 as a cancer therapeutic intended to eliminate tumor cells and is also exploring different modalities to agonize receptors for autoimmune disease modulation. ImmunOs is advancing IOS-1002 through a Phase Ia dose-escalation clinical trial as a monotherapy and in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab). The company is led by Executive Chairman Reinhard Ambros and is based in Schlieren, Switzerland. ImmunOs Therapeutics AG leverages an HLA-based technology platform to develop first-in-class therapeutics for cancer and autoimmune diseases. Its lead program, IOS-1002 (formerly iosH2), is a multi-functional fusion protein based on a naturally occurring HLA that targets LILRB1, LILRB2 and KIR3DL1 and synergizes with the adaptive immune system to drive anti-tumor activity. A Phase 1 clinical trial for IOS-1002 is planned to start in the second half of 2022, and the company intends to progress the program through Phase 2. ImmunOs is also developing antibodies to block activation of specific HLA proteins associated with autoimmune diseases and is advancing additional oncology and autoimmune programs toward clinical development. The company has established a U.S. subsidiary to expand its international reach, execute future U.S. clinical trials, and strengthen transatlantic operations and team. ImmunOs Therapeutics AG is a Swiss biotechnology company developing a new class of HLA-based biologic therapeutics for cancer and autoimmune diseases. Its proprietary R&D platform creates HLA-based therapeutics that address multiple targets via a single fusion protein; the company's lead program is a multifunctional fusion protein that blocks specific LILRB receptors to activate anti-tumor responses. ImmunOs is also developing a novel HLA‑open conformer‑specific monoclonal antibody, OCi, intended to treat immune-mediated inflammatory diseases and to act upstream of current therapies. The company plans in vivo proof-of-concept studies in spondyloarthritis and intends to extend OCi development to psoriasis and inflammatory bowel disease following successful results. Research is being conducted through an international consortium with ProteoGenix SAS (optimizing phage display for HLA mAb development) and Amsterdam UMC (providing animal models and clinical expertise). ImmunOs has received public funding from the EU’s Eurostars-2 programme and the Swiss Innovation Agency Innosuisse and is supported by investors including Pfizer Ventures, BioMed Partners and Redalpine. ImmunOs Therapeutics AG develops novel human immunomodulatory proteins that act on the innate immune system to activate anti-tumor responses. Its lead program is the iosH platform, with lead agent iosH2 being advanced as a potential treatment for both solid and liquid tumors. The company’s approach builds on research into HLA open conformer modulation of immune cells and targets diverse immunoregulatory receptors to modulate the tumor microenvironment. ImmunOs plans to complete first-in-human trials of iosH2 and to broaden the iosH platform by advancing additional preclinical programs in cancer and auto-immunity. The company is a spin-off of the University of Zurich and the University of Basel. Leadership includes CEO Sean R. Smith and CSO and co-founder Dr. Osiris Marroquin Belaunzaran, and the company states its mission is to develop novel therapeutics to improve the lives of patients with serious disease. ImmunOs Therapeutics AG is a Swiss biotechnology spin-off of the University of Zurich and University of Basel developing a next-generation platform of multitasking human immunomodulatory proteins for cancer. Its lead clinical candidate is a single multitasking protein agent aimed at treating solid tumors. The platform targets diverse immunoregulatory receptors to activate anti-tumor responses, working directly on the innate immune system (MDSCs, macrophages, NK cells and neutrophils) and indirectly on the adaptive system by enabling T cell expansion. ImmunOs positions its proteins for use both as monotherapy and in combination with checkpoint inhibitors (PD-1, CTLA-4, PD-L1) and costimulatory agonists (e.g., 4-1BB). The team brings experience in drug development and global commercialization in immunotherapy, immunology, and oncology. Proceeds from the announced financing will be used to advance the lead clinical candidate.

Total raised

$100M

Funding rounds

5

Latest round

Series C

Latest activity

Sep 2024